SCHEMBL2424315

SCHEMBL2424315

CC(O)Cc1ccc(Cl)cc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A2 P23975 1/20 0.61
SLC6A3 Q01959 1/20 0.61
SLC6A4 P31645 2/20 0.54
ACACB O00763 1/20 0.45
PPARG P37231 2/20 0.43
PPARA Q07869 2/20 0.43
IDO1 P14902 1/20 0.42
CYP1A2 P05177 1/20 0.42
CYP2D6 P10635 1/20 0.42
CYP2C19 P33261 1/20 0.42
NPC1 O15118 1/20 0.41
RAB9A P51151 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
ALDH1A1 P00352 1/20 0.41
LMNA P02545 1/20 0.41
MAPT P10636 1/20 0.41
KCNH2 Q12809 1/20 0.41
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
TAAR1 Q96RJ0 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4158699 1.00 SLC6A2 (0.61) SLC6A2SLC6A3SLC6A4ACACBPPARG
SCHEMBL4161150 1.00 SLC6A2 (0.61) SLC6A2SLC6A3SLC6A4ACACBPPARG
SCHEMBL11848580 0.88 SLC6A2 (0.50) SLC6A2SLC6A3SLC6A4ACACBMEN1
SCHEMBL196800 0.87 TAAR1 (0.48) SLC6A2SLC6A3LMNATAAR1
SCHEMBL3940696 0.84 SLC6A2 (0.59) SLC6A2SLC6A3SLC6A4ACACBPPARG
SCHEMBL19342839 0.82 SLC6A2 (0.57) SLC6A2SLC6A3SLC6A4ACACBPPARG
SCHEMBL192679 0.82 SLC6A2 (0.57) SLC6A2SLC6A3SLC6A4ACACBPPARG
SCHEMBL6642378 0.81 TAAR1 (0.40) SLC6A2SLC6A3ALDH1A1TAAR1
SCHEMBL3371824 0.81 ESR1 (0.48) ACACBIDO1LMNATAAR1
SCHEMBL2946718 0.80 SLC6A2 (0.55) SLC6A2SLC6A3SLC6A4ACACBPPARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2006013399-A1 PHARMACEUTICAL INTERMEDIATES AND A PROCESS FOR THE PREPARATION THEREOF EGIS Gyógyszergyár Rt. (HU) 2006-02-09 WO claimed
US-4474748-A ANTIBIOTICS, FUNGICIDES, ANTISEPTICS JOHNSON & JOHNSON (US) 1984-10-02 US claimed
EP-4429663-A1 HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS Vigil Neuroscience, Inc. (US) 2024-09-18 EP disclosed
CN-117466790-B Preparation method of alpha-sulfinylated carbonyl compound 西北师范大学 2024-05-28 CN disclosed
CN-117466790-A Preparation method of alpha-sulfinylated carbonyl compound 西北师范大学 2024-01-30 CN disclosed
CN-114716296-B Efficient halogenation synthesis method of alkyl halide 润药仁智(北京)科技有限公司 2023-12-12 CN disclosed
WO-2023086799-A1 HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS VIGIL NEUROSCIENCE, INC. (US) 2023-05-19 WO disclosed
CN-114716296-A Efficient halogenation synthesis method of alkyl halide 北京大学 2022-07-08 CN disclosed
CN-114634432-A High-efficiency synthesis method of alkyl aryl thioether compound 北京大学 2022-06-17 CN disclosed
US-20220144848-A1 SUBSTITUTED OXOPYRIDINE DERIVATIVES BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2022-05-12 US disclosed
EP-3898634-A1 SUBSTITUTED OXOPYRIDINE DERIVATIVES Bayer Aktiengesellschaft (DE) 2021-10-27 EP disclosed
WO-1999006408-A1 NEW 2,3-BENZODIAZEPINE DERIVATIVES Gyógyszerkutató Intézet Kft. (HU) 1999-02-11 WO disclosed
US-5807851-A MUSCLE RELAXANTS; NERVOUS SYSTEM DISORDERS EGIS GYOGYSZERGYAR RT. (HU) 1998-09-15 US disclosed
EP-0802195-A2 Substituted 2,3-benzodiazepine derivatives, process and intermediates for their preparation and pharmaceutical compositions comprising them as well as their use EGIS GYOGYSZERGYAR RT. (HU) 1997-10-22 EP disclosed
US-4474748-A ANTIBIOTICS, FUNGICIDES, ANTISEPTICS JOHNSON & JOHNSON (US) 1984-10-02 US disclosed
US-4321257-A Potentiated medicaments JOHNSON & JOHNSON (US) 1982-03-23 US disclosed
US-4197318-A CYCLOHEXYL SUBSTITUTED ALKANOLS AS POTENTIATORS JOHNSON & JOHNSON (US) 1980-04-08 US disclosed
US-4091090-A PENETRANT ACCELERATOR COMPRISING CYCLOHEXYL-SUBSTITUTED ALKANOLS JOHNSON & JOHNSON (US) 1978-05-23 US disclosed
US-4006218-A MICROBIOCIDE JOHNSON & JOHNSON (US) 1977-02-01 US disclosed
US-3991201-A 1-(β-Aryl-β-R-ethyl)imidazoles as antimicrobial agents JANSSEN PHARMACEUTICA N.V. (BE) 1976-11-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220144848-A1 SUBSTITUTED OXOPYRIDINE DERIVATIVES MVD, VASP, SELP SLC6A2 2774/4885SLC6A3 3643/4885SLC6A4 3804/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.